Panel Discussion Will Highlight Urgent Needs and Opportunities in
Antifungal Development
SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that Jeffrey Stein, Ph.D., president and chief executive
officer, will participate in a panel discussion at the 2017 BIO
International Convention being held June 19-22 in San Diego. The panel
will focus on the increasing prevalence of fungal infections and
antifungal resistance, and highlight the urgent needs and opportunities
for new antifungal development.
Dr. Stein is also the chairman of the Antimicrobials Working Group
(AWG), an industry-led coalition of emerging antimicrobial companies
that aims to provide a collective voice in policy and regulatory
solutions. He is widely considered one of the nation’s leading experts
in the discovery and development of antimicrobials. Details of the panel
discussion are as follows:
Session Title: Antifungus
Among Us: Recognizing Vulnerability and Opportunity with the
Next-Generation of Antifungals
Session ID: 22252
Date
and time: Tuesday, June 20, 2017, at 4:15 p.m. PT
Location:
San Diego Convention Center, Room 9, Upper Level
Panelists:
-
Jeffrey Stein, Ph.D., president and chief executive officer, Cidara
Therapeutics -
Tom Chiller, M.D., M.P.H., associate director for epidemiologic
science, Centers for Disease Control and Prevention (CDC) - Tim Cooke, Ph.D., chief executive officer, Novadigm Therapeutics
- Marco Taglietti, M.D., president and chief executive officer, Scynexis
-
Robert Schotzinger, M.D., Ph.D., president and chief executive
officer, Viamet Pharmaceuticals
About Fungal Infections
Approximately 97,000 Americans die from hospital-related fungal
infections each year and 90 percent of these infections are caused by
two common fungi, Candida and Aspergillus. The emergence
of a new and virulent fungal infection called Candida auris is
also a growing public health concern due its resistance to existing
antifungal agents. As of May 2017, Candida auris has been
identified in more than 120 patients in the United States and linked to
four hospital deaths, according to the Centers for Disease Control and
Prevention.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, CD101 IV, through Phase 2
and developing CD201, its bispecific antibiotic immunotherapy, for the
treatment of multi-drug resistant Gram-negative bacterial infections.
CD101 IV has improved pharmacokinetics compared to existing
echinocandins and has the potential for expanded utility across patient
settings. CD101 IV is the only once-weekly product candidate in
development for the treatment and prevention of life-threatening
invasive fungal infections. CD201 is the first drug candidate selected
from Cidara’s novel Cloudbreak™ platform, the first immunotherapy
discovery platform designed specifically to create compounds that direct
a patient’s immune cells to attack and eliminate bacterial, fungal or
viral pathogens. Cidara recently received a grant for up to $6.9 million
from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to
advance the development of CD201. Cidara is headquartered in San Diego,
California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, and other attributes
of CD101, including the potential for these compounds to successfully
treat and prevent fungal infections and simplify prophylaxis compared to
current antifungal agents. Risks that contribute to the uncertain nature
of the forward-looking statements include: the success and timing of
Cidara’s preclinical studies and clinical trials; regulatory
developments in the United States and foreign countries; changes in
Cidara’s plans to develop and commercialize its product candidates;
Cidara’s ability to obtain additional financing; Cidara’s ability to
obtain and maintain intellectual property protection for its product
candidates; and the loss of key scientific or management personnel.
These and other risks and uncertainties are described more fully in
Cidara’s Form 10-K most recently filed with the United States Securities
and Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were made.
Cidara undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on which
they were made.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170615005190/en/
Cidara Therapeutics, Inc.
INVESTOR CONTACT:
Westwicke
Partners, LLC
Robert H. Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com
